- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Coronary Syndrome
- Interventions
- fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 3,235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 4
- States / cities
- Ocala, Florida • Albuquerque, New Mexico • Syracuse, New York + 1 more
- Conditions
- Venous Thromboembolism
- Interventions
- dabigatran etexilate, standard of care
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 9
- States / cities
- Sacramento, California • Miami, Florida • Tampa, Florida + 6 more
- Conditions
- Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
- Interventions
- Edoxaban, Standard of Care
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Thromboembolism, Vaginal Cancer, Vulvar Cancer
- Interventions
- fondaparinux sodium
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Upland, Pennsylvania